Impotence – A Genetic Problem

A new discovery by scientists in Finland linking erectile dysfunction to genetic factors has raised hopes that new treatments for impotence and premature ejaculation may be developed. The scientists from Turku in Finland interviewed over 3000 men, who were all twins and the older or younger brothers of twins, about the first time they had sex and whether they experienced any sexual problems on the occasion.

The research confirms previous studies performed in Holland which suggested that men who experience premature ejaculation may share a specific gene, responsible for the production of serotonin, a hormone that regulates mood. The Finnish study seems to support the findings of the Dutch researchers.

Since it was first accepted as a medical problem, doctors have struggled to understand what causes erectile dysfunction. As with all disorders, the hope is that the more we understand the better the treatments we can develop. At the end of May, tributes were paid to the scientist who took the first steps in developing a cure for the problem, after Robert Furchgott died aged 92. Mr Furchgott in 1998 won a Nobel Prize for the work he did to show that nitric oxide played an important role in cardiovascular system. This work was used as a base for the development by drugs company Viagra Company of the first erectile dysfunction medication canadian viagra in 1998.

Many of them reported that they had suffered from impotence or premature ejaculation. While these disorders often can be attributed to external factors, such as alcohol, nerves or peer pressure – especially on the first sexual experience – the research did confirm that genetic factors also played a part.

Though its status as the ‘first’ mean many men automatically buy cialis super active over any other alternatives, in the years since it first hit the shelves other companies have produced their own versions of the drug. Levitra Company created Levitra, approved for sale in 2003, but it failed to really make its mark. In the same year, Cialis Company launched Cialis Super Active, which has proved to be Viagra’s biggest competition. While the three drugs are all roughly as effective as each other, Cialis Jelly gained a head-start due to its longer-lasting effect times, allowing men to achieve an erection for up to 36 hours after taking a tablet.

As the patents on the medications are due to run out soon, the pharmaceutical companies are very worried that generic versions of the medications will eat into their profit margins, as generic sellers are likely to dramatically slash prices. All are interested in being the first to develop the next generation of erectile dysfunction medication, something to mark them out from their competitors. Some kind of gene-based treatment might be just the thing, but promising though the Finnish study is, we are still a long way from seeing a treatment developed based on the information uncovered.

Erectile Dysfunction | Comments (0)